Drug
Cytarabine clinical trials
Also written Ara-C, Cytosar-U, CHX-3311 and U-19920.
Includes 19 studies of Liposomal Cytarabine.
- studies test it
- 556
- open now
- 82
- in phase 3
- 81
- first study started
- 1990
Keep track of what changes. Save the Cytarabine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
552 studies that test it; most in 2016 (36); 2 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1992 | 1 |
| 1993 | 3 |
| 1994 | 4 |
| 1995 | 6 |
| 1996 | 6 |
| 1997 | 4 |
| 1998 | 9 |
| 1999 | 12 |
| 2000 | 18 |
| 2001 | 17 |
| 2002 | 15 |
| 2003 | 23 |
| 2004 | 18 |
| 2005 | 17 |
| 2006 | 16 |
| 2007 | 29 |
| 2008 | 18 |
| 2009 | 20 |
| 2010 | 24 |
| 2011 | 14 |
| 2012 | 26 |
| 2013 | 18 |
| 2014 | 22 |
| 2015 | 19 |
| 2016 | 36 |
| 2017 | 16 |
| 2018 | 29 |
| 2019 | 12 |
| 2020 | 10 |
| 2021 | 10 |
| 2022 | 14 |
| 2023 | 16 |
| 2024 | 21 |
| 2025 | 16 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 186
- Phase 2
- 338
- Phase 3
- 81
- Phase 4
- 11
- No phase
- 29
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 56 · Other 500
M.D. Anderson Cancer Center (51) · National Cancer Institute (NCI) (39) · Children's Oncology Group (23) · St. Jude Children's Research Hospital (20) · Fred Hutchinson Cancer Center (17) · Institute of Hematology & Blood Diseases Hospital, China (13) · Memorial Sloan Kettering Cancer Center (11) · University of Washington (10)
Often tested with
Tested in the same studies.
Etoposide (112) · Cyclophosphamide (92) · Methotrexate (85) · Daunorubicin (83) · Vincristine (67) · Idarubicin (66) · Dexamethasone (65) · Mitoxantrone (55)
Studies
Open first, then newest update. How each study uses Cytarabine is read from its arms, and is right about nine times in ten.
Testing it · 556
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Cytarabine
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554406Written as Cytarabine
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554393Written as Cytarabine
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLRecruitingPhase 3Kura Oncology, Inc.NCT07007312Written as Cytarabine (Ara-C)
- Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease MarkerRecruitingPhase 2The Methodist Hospital Research InstituteNCT07060001Written as Cytarabine (Ara-C)
- Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT07862517Written as Cytarabine
- Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT00801489Written as Cytarabine
- Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03586609Written as Cytarabine
- Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin LymphomaRecruitingPhase 2Vanderbilt-Ingram Cancer CenterNCT07763210Written as Cytarabine
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT05554419Written as Cytarabine
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic LeukemiaRecruitingPhase 2Mayo ClinicNCT03418038Written as Cytarabine
- Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLRecruitingPhase 2OHSU Knight Cancer InstituteNCT06504459Written as Cytarabine
- Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLRecruitingPhase 1/2Heinrich-Heine University, DuesseldorfNCT05807932Written as Ara-C
- A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid LeukemiaRecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07255872Written as Cytarabine
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as Cytarabine (BAML-16-001-S1)
- A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid LeukemiaNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07754799Written as Cytarabine
- A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations DiseaseRecruitingPhase 1National Cancer Institute (NCI)NCT05886049Written as Cytarabine
- A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyRecruitingPhase 1Children's Oncology GroupNCT06247787Written as Cytarabine
- UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AMLRecruitingEarly Phase 1Baylor College of MedicineNCT07059975Written as Cytarabine (Ara-C)
- Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid LeukaemiaRecruitingPhase 3Chinese PLA General HospitalNCT07514936Written as Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte
See all 556 studies that test Cytarabine →
Given in every arm · 409 — Cytarabine is usual care beside what is tested
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLRecruitingPhase 2New York Medical CollegeNCT02393157Written as Liposomal ARA-C
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT06124157Written as Cytarabine
- Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaRecruitingPhase 1St. Jude Children's Research HospitalNCT06177067Written as Cytarabine
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as Cytarabine
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06917911Written as Cytarabine
- Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaRecruitingPhase 2OHSU Knight Cancer InstituteNCT07228273Written as Cytarabine
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT03150693Written as Cytarabine
- Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)RecruitingPhase 1/2Novartis PharmaceuticalsNCT07387926Written as Cytarabine (intrathecal)
- Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruitingPhase 2SWOG Cancer Research NetworkNCT07636564Written as Cytarabine
- Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07604233Written as Cytarabine
- Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS TumorsRecruitingPhase 2Medical University of ViennaNCT01356290Written as Cytarabine
- Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaRecruitingPhase 2City of Hope Medical CenterNCT06918431Written as Cytarabine
- Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AMLRecruitingPhase 2Beijing 302 HospitalNCT07078591Written as Cytarabine (Ara-C)
- Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute LeukemiaRecruitingPhase 1PedAL BCU, LLCNCT06376162Written as Cytarabine
- Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT00501826Written as Cytarabine
- Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)RecruitingPhase 3Stichting Hemato-Oncologie voor Volwassenen NederlandNCT07223814Written as Cytarabine
- Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsRecruitingPhase 2M.D. Anderson Cancer CenterNCT07032727Written as Cytarabine
- MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT06377540Written as Cytarabine
- Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT05645718Written as Cytarabine
- Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsRecruitingPhase 2PETHEMA FoundationNCT07507760Written as Cytarabine
Showing 20 of 409.
As the comparator · 41 — what is tested is compared with Cytarabine
- Intermediate-dose HAD Regimen for CEBPA Double-mutated AMLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06529250Written as Daunorubicin+Cytarabine
- Venetoclax Combined With Azacitidine for Consolidation Therapy in AMLRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07425782Written as Ara-C Group
- Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 MutationsNot yet recruitingPhase 2Shen yangNCT07664839Written as Cytarabine plus Daunorubicin
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AMLNot yet recruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07407140Written as Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AMLNot yet recruitingPhase 3The First Affiliated Hospital of Soochow UniversityNCT07486479Written as Cytarabine
- Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AMLRecruitingPhase 2Guangdong Provincial People's HospitalNCT06451861Written as cytarabine
- ChiCGB vs BEAM in High-risk or R/R LymphomasRecruitingPhase 3Sichuan UniversityNCT05466318Written as Cytarabine
- AML Patients Bearing FLT3 Mutations Based on Peripheral Blast ClearanceRecruitingPhase 3Gruppo Italiano Malattie EMatologiche dell'AdultoNCT04174612Written as Cytarabine
- A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young AdultsRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT02611492Written as Aracytine (Ara C)
- Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia PatientsActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04817241Written as Cytarabine
- A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) MutationCompletedPhase 3Astellas Pharma IncNCT03182244Written as Cytarabine
- Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AMLCompletedPhase 2GWT-TUD GmbHNCT04061239Written as Cytarabine
- Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and AdolescentsActive, not recruitingPhase 3Dana-Farber Cancer InstituteNCT03020030Written as CYTARABINE
- Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic LeukemiaCompletedPhase 3Technische Universität DresdenNCT02688140Written as Cytarabine
- The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)CompletedPhase 2Hospices Civils de LyonNCT00932412Written as HDAc
- A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin LymphomaActive, not recruitingPhase 3Regeneron PharmaceuticalsNCT06230224Written as Cytarabine
- A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCTActive, not recruitingPhase 2/3University of BirminghamNCT04217278Written as Cytarabine
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as Cytarabine
- Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML PatientsTerminatedPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT05361057Written as Venetoclax, daunorubicin, cytarabine
- Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Active, not recruitingPhase 3Sellas Life Sciences GroupNCT04229979Written as Cytarabine
Showing 20 of 41.
Codes
What other systems call Cytarabine · ClinicalTrials.gg INT007290
- MeSH (NLM) D003561CytarabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 04079A1RDZCYTARABINEConfirmed FDA, NLM, Wikidata
- RxNorm 3041Confirmed FDA, Wikidata
- Wikidata Q180983cytarabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C408CytarabineOne source FDA
- DrugBank DB00987One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D003561 | Cytarabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 04079A1RDZ | CYTARABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3041 | — | Confirmed FDA, Wikidata |
| Wikidata | Q180983 | cytarabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C408 | Cytarabine | One source FDA |
| DrugBank | DB00987 | — | One source Wikidata |
Also registered as cytarabine hydrochloride (UNII 33K3DB6591).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.